NCT07054879Recruiting
CtDNA-guided Maintenance Therapy in Pancreatic Cancer
A Prospective Single-center Observational Study: ctDNA-guided Maintenance Therapy for Postoperative Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 8 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to conduct a large-scale prospective clinical trial to evaluate the efficacy and safety of capecitabine monotherapy as maintenance treatment following standard adjuvant chemotherapy (gemcitabine plus capecitabine) in patients with resectable pancreatic cancer, and to analyze whether ctDNA-MRD testing can guide the selection of postoperative maintenance therapy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 70 (estimated)
- First submitted
- 27 Jun 2025
- Start date
- Nov 2024
- Primary completion date
- Dec 2025
- Lead sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Diseases
- Pancreatic cancer
- NCT number
- NCT07054879
What you commit to
- Study type: Observational
- Planned participants: 70
- From Nov 2024 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior history of radiotherapy, chemotherapy or surgical treatment for pancreatic cancer
- Concurrent severe organ dysfunction or hematologic disorders
Other illness
- Tumor involvement of celiac axis or superior mesenteric artery, locally advanced disease, or presence of distant metastases
- Poor general condition deemed unable to tolerate chemotherapy
- History of other malignancies within past 5 years (except adequately treated carcinoma in situ of cervix or basal cell carcinoma of skin)
- Any severe or uncontrolled systemic disease that may affect risk/benefit assessment, including but not limited to: uncontrolled hypertension, active hepatitis B or C infection, HIV infection
- Any other condition that in the investigator's judgment would make the patient unsuitable for study participation
Other
- Patient or guardian unable to comprehend study objectives and requirements
Who the study is looking for
- Age ≥18 years, male or female
- Histologically or cytologically confirmed primary diagnosis of pancreatic ductal adenocarcinoma (PDAC)
- No evidence of distant metastasis (M0)
- Underwent R0 radical resection within 3 months prior to enrollment
- ECOG performance status of 0-1
- Life expectancy ≥3 months
- Patient or legal guardian is able to understand the study requirements and willing to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nanjing Drum Tower hospital Coordinator of this site? Confirm its status | Nanjing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.